Scattering of Bunched Fractionally Charged Quasiparticles

The charge of fractionally charged quasiparticles, proposed by Laughlin to explain the fractional quantum Hall effect (FQHE), was recently verified by measurements. Charge q=e/3 and e/5 (e is the electron charge), at filling factors nu=1/3 and 2/5, respectively, were measured. Here we report the unexpected bunching of fractional charges, induced by an extremely weak backscattering potential at exceptionally low electron temperatures (T<10 mK) - deduced from shot noise measurements. Backscattered charges q=nu e, specifically, q=e/3, q=2e/5, and q<3e/7, in the respective filling factors, were measured. For the same settings but at an only slightly higher electron temperature, the measured backscattered charges were q=e/3, q=e/5, and q=e/7. In other words, bunching of backscattered quasiparticles is taking place at sufficiently low temperatures. Moreover, the backscattered current exhibited distinct temperature dependence that was correlated to the backscattered charge and the filling factor. This observation suggests the existence of 'low' and 'high' temperature backscattering states, each with its characteristic charge and characteristic energy.Comment: 4 pages, 3 figure

Ising films with surface defects

The influence of surface defects on the critical properties of magnetic films is studied for Ising models with nearest-neighbour ferromagnetic couplings. The defects include one or two adjacent lines of additional atoms and a step on the surface. For the calculations, both density-matrix renormalization group and Monte Carlo techniques are used. By changing the local couplings at the defects and the film thickness, non-universal features as well as interesting crossover phenomena in the magnetic exponents are observed.Comment: 8 pages, 12 figures included, submitted to European Physical Journal

Entanglement scaling in critical two-dimensional fermionic and bosonic systems

We relate the reduced density matrices of quadratic bosonic and fermionic models to their Green's function matrices in a unified way and calculate the scaling of bipartite entanglement of finite systems in an infinite universe exactly. For critical fermionic 2D systems at T=0, two regimes of scaling are identified: generically, we find a logarithmic correction to the area law with a prefactor dependence on the chemical potential that confirms earlier predictions based on the Widom conjecture. If, however, the Fermi surface of the critical system is zero-dimensional, we find an area law with a sublogarithmic correction. For a critical bosonic 2D array of coupled oscillators at T=0, our results show that entanglement follows the area law without corrections.Comment: 4 pages, 4 figure

Controlling internal barrier in low loss BaTiO3 supercapacitors

Supercapacitor behavior has been reported in a number of oxides including reduced BaTiO3 ferroelectric ceramics. These so-called giant properties are however not easily controlled. We show here that the continuous coating of individual BaTiO3 grains by a silica shell in combination with spark plasma sintering is a way to process bulk composites having supercapacitor features with low dielectric losses and temperature stability. The silica shell acts both as an oxidation barrier during the processing and as a dielectric barrier in the final composite

Nuclear matrix protein 2 antibody-positive adult dermatomyositis: a case report and review of the literature

Dermatomyositis is a clinically heterogenous inflammatory myopathy with unique cutaneous features. Myositis-specific antibodies can aid in diagnosis and anticipation of patient prognosis. Herein, we report a 22-year-old man who presented with multifocal erythematous plaques with violaceous papules on his bilateral elbows, neck, and face. He was diagnosed with biopsy-proven dermatomyositis and determined to be seropositive for nuclear matrix protein 2 antibody (NXP-2). He was treated with systemic corticosteroids, then intravenous methylprednisolone and azathioprine, and ultimately achieved greatest treatment response with intravenous immune globulin therapy